6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16

OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2017

Commission file number: 001-36621

FOAMIX PHARMACEUTICALS LTD.

(Translation of registrant's name into English)

2 Holzman Street, Weizmann Science Park

Rehovot, Israel (Address of principal executive office)

_____________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   

Form 20-F S           Form 40-F £

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): £

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): £

CONTENTS

This report on Form 6-K of the registrant consists of (i) a press release issued by the registrant on March 27, 2017, and (ii) a presentation dated March 2017, each of which is attached hereto as an exhibit and incorporated by reference herein.

The information contained in this Form 6-K is incorporated by reference into (i) the registration statement on Form S-8 (number 333-199486) of the registrant, filed with the Securities and Exchange Commission (the "SEC"), as amended by the post-effective registration statement on Form S-8 POS filed February 5, 2016, (ii) the registration statement on Form S-8 (number 333-209403) of the registrant, filed with the SEC, and (iii) the registration statement on Form F-3 (333-216224) of the registrant, filed with the SEC on February 24, 2017, in each case to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

Exhibits

99.1	Press release: Foamix Reports Topline Results from Phase 3 Trials for FMX101 in Patients with Acne
99.2	Presentation: FMX101 Topical 4% Minocycline Foam for Moderate-to-Severe Acne – Phase 3 Results

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

FOAMIX PHARMACEUTICALS  LTD. (Registrant)
By:	/s/ Ilan Hadar
	Name: Ilan Hadar
	Title:   Chief Financial Officer

Date: March 27, 2017

2

EX-99.1

Exhibit 99.1

Foamix Reports Topline Results from Phase 3 Trials for

FMX101 in Patients with Acne

Conference Call and Webcast Today at 8:30 a.m. EDT

REHOVOT, Israel, and BRIDGEWATER, NJ – March 27, 2017 – Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), today announced the topline results of its two Phase 3 clinical trials investigating FMX101, Trial 04 and Trial 05, in patients with moderate-to-severe acne.

In the intent-to-treat analysis, FMX101 demonstrated statistical significance compared to vehicle on both co-primary endpoints in Trial 05, but did not demonstrate statistical significance on one of the two co-primary endpoints in Trial 04, specifically IGA success.

Key top-line data:

· Co-primary endpoint - Absolute changes from baseline in the number of inflammatory lesions

· Trial 04: -14.16 for FMX101 and -11.17 for the vehicle (p=0.0071); percent reductions were 43.93% for FMX101 and 34.03% for the vehicle (p<0.01)

· Trial 05: -13.46 for FMX101 and -10.72 for vehicle (p=0.0058); percent reductions were 42.94% for FMX101 and 33.94% for vehicle in Trial 05 (p<0.01)

· Co-primary endpoint - Proportions of patients with  Investigator's Global Assessment (IGA) success

· Trial 04: 8.09% for FMX101 and 4.77% for the vehicle (p=0.2178)

· Trial 05: 14.67% for FMX101 and 7.89% for the vehicle (p=0.0423)

· FMX101 was generally safe and well-tolerated.

“Whereas Trial 05 showed significance in both primary endpoints, Trial 04 did not meet significance for the IGA score endpoint,” said Dov Tamarkin, Ph.D., CEO of Foamix. “Our team has not yet received the full data set and we intend to provide an update on the program as soon as we complete our analysis.  As we have previously announced, the safety extensions for trials 04 and 05 are fully enrolled and continue as planned.”

The two double-blind, randomized, placebo-controlled Phase 3 trials (Trials No. 04 and 05) included a total of 961 subjects with moderate-to-severe acne. Subjects were randomized to receive either FMX101 (minocycline foam 4%) or vehicle foam once daily over 12 weeks.

The two co-primary endpoints were the absolute change in the number of inflammatory lesions (papules and pustules); and the proportion of patients achieving success at week 12, as defined by an IGA score of “clear” or “almost clear” and at least a two-grade improvement from baseline at week 12.

As stated in our recent earnings call, as of Dec. 31, 2016, Foamix had cash and investments of $131 million. We expect our cash and investments to fund our operations into mid-2019 including the continued development of our pipeline.

Conference Call Information

March 27th, 2017 @ 8.30am EDT

Investors: 1-888-599-8686

International: 1-913-312-1486

Israel Investors: 1 80 924 6064

Conference ID: 9541840

Webcast: http://public.viavid.com/index.php?id=123589

Replays, Available through April 9th:

Toll-Free: 1-877-870-5176

International: 1-858-384-5517

Replay PIN: 9541840

About Foamix Pharmaceuticals

Foamix is a specialty pharmaceutical company focused on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy. Our clinical stage product candidates include FMX101, our novel minocycline foam for the treatment of moderate-to-severe acne, FMX103 for the treatment of moderate-to-severe rosacea, FMX102 for the treatment of impetigo, and FDX104, our doxycycline foam for the management of acne-like rash induced by EGFRI anticancer drugs.

In addition, we have development and license agreements relating to our technology with various pharmaceutical companies including Bayer HealthCare and others.

For more information, please visit www.foamixpharma.com.

Forward Looking Statements

This press release may include forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995.  Forward-looking statements are statements that are not historical facts, such as statements regarding assumptions, expectations, forecasts, beliefs or intentions related to financial results, commercial results, timing and results of clinical trials and U.S. FDA and other regulatory agencies authorizations.  Forward-looking statements are based on our current knowledge and our present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions.  Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of various factors including, but not limited to, unexpected delays, excess costs or unfavorable results of clinical trials, delays or denial in the U.S. FDA approval process, additional competition in the acne market, denial of reimbursement by third party payors or inability to raise additional capital.  We discuss many of these risks in greater detail under the heading “Risk Factors” in our most recent Annual Report on Form 20-F (File No. 17625089) filed on February 21, 2017 and elsewhere in that Annual Report. Any forward-looking statements that may be made herein speak only as of the date of this release and Foamix undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

Corporate Contact:

Ilan Hadar, CFO

Foamix Pharmaceuticals Ltd.

+972-8-9316233

ilan.hadar@foamixpharma.com

U.S. Investor Relations

Michael Rice

LifeSci Advisors, LLC

646-597-6979

mrice@lifesciadvisors.com

Media

Matt Middleman, M.D.

LifeSci Public Relations

646-627-8384

matt.middleman@lifescipublicrelations.com

EX-99.2

Exhibit 99.2

           Nasdaq: FOMX  FMX101 Topical 4% Minocycline Foam for Moderate-to-Severe AcnePhase 3 ResultsMarch 2017 

 Disclaimer  To the extent that statements contained in this presentation are not descriptions of historical facts regarding Foamix, they are forward-looking statements reflecting management’s current beliefs and expectations. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels of activity, performance, or achievements to be materially different from those anticipated by such statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “intends,” or “continue,” or the negative of these terms or other comparable terminology. Forward-looking statements contained in this presentation include, but are not limited to, (i) statements regarding the timing of anticipated clinical trials for our product candidates; (ii) the timing of receipt of clinical data for our product candidates; (iii) our expectations regarding the potential safety, efficacy, or clinical utility of our product candidates; (iv) the size of patient populations targeted by our product candidates and market adoption of our product candidates by physicians and patients; (v) the timing or likelihood of regulatory filings and approvals; and (vi) our revenues under our agreements with our licensees, including Bayer, Allergan and Merz. Although we believe that the expectations reflected in the forward-looking statements are reasonable, various factors may cause differences between our expectations and actual results, including, but not limited to, unexpected safety or efficacy data, unexpected side effects observed during preclinical studies or in clinical trials, lower than expected enrollment rates in clinical trials, changes in expected or existing competition, changes in the regulatory environment for our product candidates and our need for future capital, the inability to protect our intellectual property, and the risk that we become a party to unexpected litigation or other disputes. You should read the documents filed by Foamix with the SEC, including our prospectuses, the Risk Factors set forth therein and the documents filed as exhibits to our registration statements, of which the prospectuses are a part, completely and with the understanding that our actual future results may be materially different from what we expect.  You may obtain those documents by visiting EDGAR on the SEC website at www.sec.gov. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of the foam technology or product candidates of Foamix.  2 

 Phase 3 Pivotal Clinical Studies   3  Protocol FX2014-04 and Protocol FX2014-05  A Randomized, Double-Blind Trial to Compare the Efficacy, Safety and Long-Term Safety of Topical Administration of FMX-101 for 1 Year in the Treatment of Moderate-to-Severe Acne Vulgaris 

 Phase 3: Design of Each Pivotal Trial (x2)  Self-apply, once daily, in the evening, for 12 weeksInclusion criteriaAt least 20 inflammatory and 25 non-inflammatory lesionsIGA 6 point scale – Moderate or Severe (Grade 3 or 4) Co-Primary Efficacy EndpointsMean change from baseline in inflammatory lesion countProportion of subjects with IGA scores of “Clear” or “Almost Clear”, with improvement of at least 2 grades from baseline  4  12-week, randomized, double-blind, vehicle controlled, in subjects with moderate-to-severe acne; followed by 9 month open label safety extension  Week 12(End of treatment)  12 Months  Week 3  Week 6  Week 9      Double-blinded PhaseRandomized (2:1), double-blindN = 450    Minocycline foam 4% – 9 months of treatment    Open Label Safety Extension Subjects who complete one of the randomized, Phase 3 studies may enter the open-label phase  Minocycline Foam 4%Foam vehicle  Baseline 

 Acne Phase 3  5  Baseline Data  Total number of subjects: 466 (Trial 04) 495 (Trial 05)Mean age: 20.3 20.6Male/Female: M=42.9% F=57.1% M=41.4% F=58.6%Ethnicity: W=62.7% B=27.0% O=10.3% W=74.1% B=20.8% O=5.0%     Trial 04    Trial 05      FMX-101, 4%(N = xxx)  Vehicle(N = xxx)  FMX-101, 4%(N = xxx)  Vehicle(N = xxx)  Baseline Inflammatory Lesion Counts            Mean (SD)  32.2(8.4)  31.6(8.6)  31.6(8.6)  32.3(8.0)   Median   31  30  30  31   Range (min-max)  20-50  20-76  20-69  20-50  Baseline Non-inflammatory Lesion Counts            Mean (SD)  49.5(18.0)  46.5(16.6)  50.5(19.5)  50.9(19.9)  Baseline Total Lesion Counts            Mean (SD)  81.7(21.3)  78.1(19.7)  81.5(21.9)  83.1(23.2)  Baseline IGA Score, n (%)            3 – Moderate  255(83.1)  137(86.2)  296(88.9)  148(91.4)   4 – Severe  52(16.9)  22(13.8)  37(11.1)  14(8.6) 

     P<.01*      6  *Intent to Treat (ITT) Population; ANCOVA; multiple imputation method  P<.01*  n=307  n=159  n=333  n=162  FMX101  Vehicle  FMX101  Vehicle  Acne Phase 3 Efficacy ResultsReduction of Inflammatory Lesion Count at Week 12  In Trial 04, absolute change in inflammatory lesion count for the FMX101, 4% treatment group was 14.16 versus 11.17 in vehicle (p=0.0071) In Trial 05, absolute change in inflammatory lesion count for the FMX101, 4% treatment group was 13.46 versus 10.72 in vehicle (p=0.0058)  

     P<.05*      P>0.21*  7  n=307  n=159  n=333  n=162  FMX101  Vehicle  FMX101  Vehicle  Acne Phase 3 Efficacy ResultsIGA Treatment Success at Week 12 [Score Clear (0) or Almost Clear (1)]  In Trial 04, IGA Treatment Success for FMX101, 4% treatment group was 8.09% versus 4.77% in vehicle (p=0.2178) In Trial 05, IGA Treatment Success for FMX101, 4% treatment group was 14.67% versus 7.89% in vehicle (p=0.0423)   *Intent to Treat (ITT) Population; Cochran–Mantel–Haenszel test; multiple imputation method  

     P<.01*      P<.01*  8  n=307  n=159  n=333  n=162  FMX101  Vehicle  FMX101  Vehicle  Acne Phase 3 Efficacy Results% Change of Inflammatory Lesion Count at Week 12  In Trial 04, percent change in inflammatory lesion count for the FMX101, 4% treatment group was 43.93% versus 34.03% in vehicle (p=0.0033) In Trial 05, percent change in inflammatory lesion count for the FMX101, 4% treatment group was 42.94% versus 34.30% in vehicle (p=0.0097)   *Intent to Treat (ITT) Population; ANCOVA; multiple imputation method 

     P>0.14*      P<.05*  9  n=307  n=159  n=333  n=162  FMX101  Vehicle  FMX101  Vehicle  Acne Phase 3 Efficacy ResultsIGA Treatment Improvement > 2-grade at Week 12  In Trial 04, > 2-grade IGA Improvement for FMX101, 4% treatment group was 13.39% versus 8.99% in vehicle (p=0.1435) In Trial 05, > 2-grade IGA Improvement for FMX101, 4% treatment group was 17.26% versus 8.64% in vehicle (p=0.0165)   *Intent to Treat (ITT) Population; Cochran–Mantel–Haenszel test; multiple imputation method  

 Acne Phase 3 Safety Results   10  Overall AE Frequency*  FMX101 – Generally Safe and Well Tolerated  Trial 04 AE Frequency (%)      Adverse Event  FMX101, 4%  Vehicle  One or more  16.9  18.2  Nasopharyngitis  2.0  3.8  Headache  2.3  3.1  CK increase  1.0  0.6  Ligament sprain  0.3  1.3  Nausea  0.7  0.6  Trial 05 AE Frequency (%)      Adverse Event  FMX101, 4%  Vehicle  One or more  33.0  26.5  Nasopharyngitis  7.2  3.7  Headache  6.0  5.6  Upper Respiratory Tract Infection  1.8  1.2  Ligament Sprain  1.8  0.6  CK increased  1.5  2.5  Nausea  1.2  0.6  Vomiting  1.2  0.6  * Non-dermal AEs occurring in at least 1% of subjects in either group 

 Acne Phase 3 Safety Results - Summary   11  The most common systemic adverse event was nasopharyngitis in both studies; overall 2.6% in Trial 04 and 6.1% in Trial 05Dermal adverse events were few; most were mild and included instances of acne, dermatitis, rash and discoloration.No drug-related serious adverse events were reported A total of 4 subjects discontinued the Trial due to an adverse event including 2 in the active group (pruritus, worsening acne) and 2 in the vehicle group (ectopic pregnancy, elevated liver enzymes).FMX101 was generally safe and well tolerated. 

 Question & Answer